Should I buy or sell Sarepta Therapeutics stock right now?

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last year. There are currently 3 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" SRPT shares. View SRPT analyst ratings or view top-rated stocks .

What is Sarepta Therapeutics' stock price target for 2024?

15 Wall Street research analysts have issued 12-month target prices for Sarepta Therapeutics' shares. Their SRPT share price targets range from $109.00 to $224.00. On average, they expect the company's share price to reach $158.38 in the next twelve months. This suggests a possible upside of 34.3% from the stock's current price. View analysts price targets for SRPT or view top-rated stocks among Wall Street analysts .

How have SRPT shares performed in 2024?

Sarepta Therapeutics' stock was trading at $96.43 on January 1st, 2024. Since then, SRPT stock has increased by 22.3% and is now trading at $117.89. View the best growth stocks for 2024 here .

When is Sarepta Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our SRPT earnings forecast .

How were Sarepta Therapeutics' earnings last quarter?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced its quarterly earnings data on Wednesday, February, 28th. The biotechnology company reported $0.47 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.50. The biotechnology company had revenue of $396.80 million for the quarter, compared to the consensus estimate of $387.18 million. Sarepta Therapeutics had a negative net margin of 43.11% and a negative trailing twelve-month return on equity of 18.97%. The firm's revenue was up 53.6% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.24) earnings per share.

What ETFs hold Sarepta Therapeutics' stock?

ETFs with the largest weight of Sarepta Therapeutics (NASDAQ:SRPT) stock in their portfolio include Simplify Health Care ETF (PINK) , Morningstar US Small Growth (MSGR) , Global X Genomics & Biotechnology ETF (GNOM) , iShares Neuroscience and Healthcare ETF (IBRN) , First Trust NYSE Arca Biotechnology Index Fund (FBT) , Virtus LifeSci Biotech Products ETF (BBP) , Principal Healthcare Innovators ETF (BTEC) and VanEck Biotech ETF (BBH) .

What is Douglas S. Ingram's approval rating as Sarepta Therapeutics' CEO?

15 employees have rated Sarepta Therapeutics Chief Executive Officer Douglas S. Ingram on Glassdoor.com . Douglas S. Ingram has an approval rating of 95% among the company's employees. This puts Douglas S. Ingram in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Sarepta Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT) , NVIDIA (NVDA) , Micron Technology (MU) , Advanced Micro Devices (AMD) , Gilead Sciences (GILD) , Alibaba Group (BABA) , Netflix (NFLX) , Tesla (TSLA) , AbbVie (ABBV) and Walt Disney (DIS) .

Who are Sarepta Therapeutics' major shareholders?

Sarepta Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Wealth Enhancement Advisory Services LLC (0.01%), Atwood & Palmer Inc. (0.00%), GAMMA Investing LLC (0.00%) and Mather Group LLC. (0.00%). Insiders that own company stock include Bilal Arif, Douglas S Ingram , Hans Lennart Rudolf Wigzell , Ian Michael Estepan, Kathryn Jean Boor, Louise Rodino-Klapac , Michael Andrew Chambers , Richard Barry and Stephen Mayo . View institutional ownership trends .

How do I buy shares of Sarepta Therapeutics?

Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does Sarepta Therapeutics have any subsidiaries?

The following companies are subsidiares of Sarepta Therapeutics: Eisai, Myonexus Therapeutics, ST International Holdings Two Inc., Sarepta Securities Corp., and Sarepta Therapeutics Three LLC. Read More

NASDAQ:SRPT

Sarepta Therapeutics (SRPT) Stock Price, News & Analysis

→ Biden to Launch “FedNOW” [Move Your Money Now] (From Priority Gold) (Ad)

Free SRPT Stock Alerts

$117.89

+0.60 (+0.51%)

(As of 04/17/2024 ET)

Compare

Today's Range: $115.93
▼
$119.08
50-Day Range: $117.29
▼
$141.53
52-Week Range: $55.25
▼
$159.89

Volume: 546,120 shs
Average Volume: 996,662 shs
Market Capitalization: $11.07 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $158.38

Get Sarepta Therapeutics alerts:

Sarepta Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 34.3% Upside
$158.38 Price Target
Short Interest: Healthy
4.90% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.65
Upright™ Environmental Score
News Sentiment: 0.96
Based on 8 Articles This Week
Insider Trading: Selling Shares
$2.74 M Sold Last Quarter
Proj. Earnings Growth: 278.50%
From $2.14 to $8.10 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.87 out of 5 stars

Medical Sector

25th out of 913 stocks

Pharmaceutical Preparations Industry

10th out of 396 stocks

4.4

Analyst's Opinion

Consensus Rating
Sarepta Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 12 buy ratings, 3 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Sarepta Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

4.0

Short Interest

Percentage of Shares Shorted
4.90% of the outstanding shares of Sarepta Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Sarepta Therapeutics has a short interest ratio ("days to cover") of 4.5.
Change versus previous month
Short interest in Sarepta Therapeutics has recently decreased by 7.44%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Sarepta Therapeutics does not currently pay a dividend.
Dividend Growth
Sarepta Therapeutics does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Sarepta Therapeutics has received a 62.32% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Neuromuscular disorders medication", "Clinical research services", and "Preclinical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Sarepta Therapeutics is -1.65.

2.2

News and Social Media Coverage

News Sentiment
Sarepta Therapeutics has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for Sarepta Therapeutics this week, compared to 9 articles on an average week.
Search Interest
Only 16 people have searched for SRPT on MarketBeat in the last 30 days. This is a decrease of -62% compared to the previous 30 days.
MarketBeat Follows
Only 7 people have added Sarepta Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -42% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Sarepta Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,739,419.00 in company stock.
Percentage Held by Insiders
Only 7.40% of the stock of Sarepta Therapeutics is held by insiders.
Percentage Held by Institutions
86.68% of the stock of Sarepta Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Sarepta Therapeutics are expected to grow by 278.50% in the coming year, from $2.14 to $8.10 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Sarepta Therapeutics is -19.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Sarepta Therapeutics is -19.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Sarepta Therapeutics has a P/B Ratio of 12.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Insiders Exposed

This consistently signaled gains of 453%... 610%... and even 1036%...

It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.

About Sarepta Therapeutics Stock (NASDAQ:SRPT)

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

SRPT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SRPT Stock News Headlines

April 15, 2024 | nasdaq.com

RSI Alert: Sarepta Therapeutics (SRPT) Now Oversold

April 13, 2024 | finance.yahoo.com

10 Unstoppable Stocks That Will Make You Richer

April 18, 2024 | Insiders Exposed (Ad)

The Hard Truth About Investing For Retirement

Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.

April 11, 2024 | seekingalpha.com

Pfizer: The Market Is Wrong

April 11, 2024 | seekingalpha.com

Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy

April 10, 2024 | markets.businessinsider.com

Sarepta Therapeutics: A Buy Recommendation Amidst Undervaluation and Growth Potential for Elevidys

April 8, 2024 | seekingalpha.com

Sarepta Therapeutics: Another 'Hold' Call Ahead Of Some Key Catalysts

April 8, 2024 | finance.yahoo.com

Why Sarepta's First-Quarter Report Is Already Dead In The Water: Analyst

April 18, 2024 | Insiders Exposed (Ad)

The Hard Truth About Investing For Retirement

April 7, 2024 | msn.com

RBC sees Sarepta's Elevidys remaining on market: report

April 6, 2024 | fool.com

2 Biotech Stocks to Buy Hand Over Fist in April

April 5, 2024 | markets.businessinsider.com

Buy Rating on Sarepta Therapeutics Amidst Anticipated Drug Approval and Market Potential

March 29, 2024 | businesswire.com

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 26, 2024 | bizjournals.com

Trial results for Dravet drug spurs stock surge at Bedford biotech

March 25, 2024 | finance.yahoo.com

A Comprehensive Look at Sarepta's Growth and Innovation

March 19, 2024 | ca.finance.yahoo.com

SRPT Jun 2024 80.000 call

March 13, 2024 | markets.businessinsider.com

Buy Rating for Sarepta Therapeutics Amidst Promising Developments and Strategic Partnerships

March 13, 2024 | fool.com

Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?

March 12, 2024 | finance.yahoo.com

Director Wigzell Hans Lennart Rudolf Sells 15,000 Shares of Sarepta Therapeutics Inc (SRPT)

March 9, 2024 | uk.finance.yahoo.com

SRPT Mar 2024 80.000 put

March 8, 2024 | fool.com

Got $1,000? Buy These Hot Growth Stocks Before They Take Off.

March 7, 2024 | finance.yahoo.com

Director Stephen Mayo Sells 3,135 Shares of Sarepta Therapeutics Inc (SRPT)

March 6, 2024 | markets.businessinsider.com

Sarepta Therapeutics’ Elevidys Poised for Market Leadership in DMD, Despite Emerging Competitors

March 4, 2024 | fool.com

Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst

March 4, 2024 | businesswire.com

Sarepta Therapeutics to Present at Upcoming Investor Conferences

March 2, 2024 | finance.yahoo.com

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

March 2, 2024 | gurufocus.com

Decoding Sarepta Therapeutics Inc (SRPT): A Strategic SWOT Insight

See More Headlines

Receive SRPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/07/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:SRPT
Previous Symbol: NASDAQ:AVII
CUSIP: N/A
CIK: 873303
Web: www.sareptatherapeutics.com
Phone: (617) 274-4000
Fax: 425-354-5038
Employees: 1,314
Year Founded: 1980

Price Target and Rating

Average Stock Price Target: $158.38
High Stock Price Target: $224.00
Low Stock Price Target: $109.00
Potential Upside/Downside: +34.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.80
Research Coverage: 15 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($6.12)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 55.09
P/E Growth: N/A
Net Income: $-535,980,000.00
Net Margins: -43.11%
Pretax Margin: -41.83%
Return on Equity: -18.97%
Return on Assets: -4.65%

Debt

Debt-to-Equity Ratio: 1.32
Current Ratio: 3.95
Quick Ratio: 3.45

Sales & Book Value

Annual Sales: $1.24 billion
Price / Sales: 8.90
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $9.19 per share
Price / Book: 12.83

Miscellaneous

Outstanding Shares: 93,900,000
Free Float: 86,951,000
Market Cap: $11.07 billion
Optionable: Optionable
Beta: 0.94

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. Douglas S. Ingram Esq. (Age 61)
President, CEO & Director
Comp: $1.62M
Mr. Ian Michael Estepan (Age 48)
Executive VP & CFO
Comp: $917.53k
Dr. Louise R. Rodino-Klapac Ph.D. (Age 46)
Executive VP, Chief Scientific Officer and Head of Research & Development
Comp: $1.04M
Mr. Ryan E. Brown J.D. (Age 46)
Executive VP, General Counsel & Corporate Secretary
Comp: $823.36k
Mr. Bilal Arif (Age 52)
Executive VP & Chief Technical Operations Officer
Ms. Francesca T. Nolan
Executive Director of Investor Relations and Corporate Communications
Ms. Alison Nasisi
Executive VP & Chief People Officer
Dr. Diane L. Berry Ph.D.
Executive VP and Chief of Global Policy & Advocacy Officer
Mr. Dallan Murray
Executive VP & Chief Customer Officer
Mr. Will Tilton
Senior VP, Head of Strategy & Chief of Staff

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SRPT Stock Analysis - Frequently Asked Questions

Should I buy or sell Sarepta Therapeutics stock right now?: 15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last year. There are currently 3 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" SRPT shares.
View SRPT analyst ratings or view top-rated stocks.
What is Sarepta Therapeutics' stock price target for 2024?: 15 Wall Street research analysts have issued 12-month target prices for Sarepta Therapeutics' shares. Their SRPT share price targets range from $109.00 to $224.00. On average, they expect the company's share price to reach $158.38 in the next twelve months. This suggests a possible upside of 34.3% from the stock's current price.
View analysts price targets for SRPT or view top-rated stocks among Wall Street analysts.
How have SRPT shares performed in 2024?: Sarepta Therapeutics' stock was trading at $96.43 on January 1st, 2024. Since then, SRPT stock has increased by 22.3% and is now trading at $117.89.
View the best growth stocks for 2024 here.
When is Sarepta Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our SRPT earnings forecast.
How were Sarepta Therapeutics' earnings last quarter?: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced its quarterly earnings data on Wednesday, February, 28th. The biotechnology company reported $0.47 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.50. The biotechnology company had revenue of $396.80 million for the quarter, compared to the consensus estimate of $387.18 million. Sarepta Therapeutics had a negative net margin of 43.11% and a negative trailing twelve-month return on equity of 18.97%. The firm's revenue was up 53.6% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.24) earnings per share.
What ETFs hold Sarepta Therapeutics' stock?: ETFs with the largest weight of Sarepta Therapeutics (NASDAQ:SRPT) stock in their portfolio include Simplify Health Care ETF (PINK), Morningstar US Small Growth (MSGR), Global X Genomics & Biotechnology ETF (GNOM), iShares Neuroscience and Healthcare ETF (IBRN), First Trust NYSE Arca Biotechnology Index Fund (FBT), Virtus LifeSci Biotech Products ETF (BBP), Principal Healthcare Innovators ETF (BTEC) and VanEck Biotech ETF (BBH).

What is Douglas S. Ingram's approval rating as Sarepta Therapeutics' CEO?: 15 employees have rated Sarepta Therapeutics Chief Executive Officer Douglas S. Ingram on Glassdoor.com. Douglas S. Ingram has an approval rating of 95% among the company's employees. This puts Douglas S. Ingram in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Sarepta Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV) and Walt Disney (DIS).
Who are Sarepta Therapeutics' major shareholders?: Sarepta Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Wealth Enhancement Advisory Services LLC (0.01%), Atwood & Palmer Inc. (0.00%), GAMMA Investing LLC (0.00%) and Mather Group LLC. (0.00%). Insiders that own company stock include Bilal Arif, Douglas S Ingram, Hans Lennart Rudolf Wigzell, Ian Michael Estepan, Kathryn Jean Boor, Louise Rodino-Klapac, Michael Andrew Chambers, Richard Barry and Stephen Mayo.
View institutional ownership trends.
How do I buy shares of Sarepta Therapeutics?: Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does Sarepta Therapeutics have any subsidiaries?: The following companies are subsidiares of Sarepta Therapeutics: Eisai, Myonexus Therapeutics, ST International Holdings Two Inc., Sarepta Securities Corp., and Sarepta Therapeutics Three LLC.
Read More

This page (NASDAQ:SRPT) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial